Asia Pac Allergy.  2019 Apr;9(2):e14. 10.5415/apallergy.2019.9.e14.

Successful cholecalciferol desensitisation in a case of delayed hypersensitivity

  • 1Department of Immunology, The Canberra Hospital, Canberra, ACT 2606, Australia.
  • 2John Curtin School of Medical Research, Australian National University, Canberra, ACT 2601, Australia.
  • 3Department of Pharmacy, St Vincent's Hospital, Darlinghurst, NSW 2010, Australia.
  • 4Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia.
  • 5HIV, Immunology & Infectious Diseases Unit, St Vincent's Hospital, Darlinghurst, NSW 2010, Australia.
  • 6Centre for Applied Medical Research, St Vincent's Hospital, Darlinghurst, NSW 2010, Australia.


Hypersensitivity to cholecalciferol (vitamin D3) or its active metabolite, calcitriol, is an exceedingly rare clinical phenomenon, with only 2 previously reported cases of suspected immediate hypersensitivity. Diagnosis of delayed drug hypersensitivity reactions is inherently difficult due to the lack of any robust in vitro diagnostic assay, particularly in those patients for whom provocation testing confers an unacceptable risk. In these situations, diagnosis relies on reproducible clinical manifestations following administration of the culprit agent, resolution upon its withdrawal and exclusion of other potential differential diagnoses. Based on these criteria, we propose the first reported case of delayed hypersensitivity to cholecalciferol successfully managed with a desensitisation protocol to pure cholecalciferol.


Drug hypersensitivity; Cholecalciferol; Calcitriol; Immunologic desensitisation
Full Text Links
  • APA
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: